Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarceva and Avastin in Metastatic Melanoma
NCT00466687Phase 2Completed
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Sep 2004
- Primary completion
- Aug 2008
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib and bevacizumab in melanoma, sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoints: Overall Response Rate at 6 months, Response Duration and 2 more. Started Sep 2004; status: completed.
02
Drugs
erlotinibbevacizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00466687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00466687.